L

Latigo Biotherapeutics

LTGOPro tracking

Latigo Biotherapeutics, Inc. · Nasdaq · Non-opioid pain therapeutics · Research source · 424B4 · Research as of 2026/08/07 · Latest filing · 10-Q · 2026-11-05 SEC ↗ · SEC checked 2026-11-21

SEC
Saved research available · 424B4

Latigo Biotherapeutics is offering 19.2 million shares of common stock at $18.00 per share under ticker LTGO, with estimated net proceeds of approximately $315.7 million.

Research source · 424B4 · Research as of 2026/08/07Latest analyzed filing · 424B4 · 2026-08-07

Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.

SummaryWATCHReport source · 424B4

Newly listed — review valuation, deal quality and post-IPO supply before acting

A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition. The IPO priced at $18.00 and raised $345.60M.

Full source-backed summary

A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition. The IPO priced at $18.00 and raised $345.60M. The latest market-value reference is $1.41B; reported revenue is Pre-revenue and net result is $(111.18M). The offer figures are reconciled to the final prospectus.

Net cash used in operating activities($97,557,000)FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Voting controlNo controlling party conclusion availableNot separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
Business and development direction

A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition.

Current business

Non-opioid pain therapeutics100%

Future development

Future direction not yet disclosed

DECISION DRIVERS

Key risks

High

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

High

Risk 2

The latest reported period remains loss-making.

High

Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

NEXT EVENTFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility
LATEST EVIDENCE424B42026/08/07
LISTING CHECKPOINT2026-08-07Nasdaq
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualityThis saved report has no compatible source inputs for this calculation. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
CONFIRMED
#InstitutionUnderwriting allocationRatio · calculatedShares
1Goldman Sachs & Co. LLC39.00%7,488,000 shares
2Jefferies LLC28.00%5,376,000 shares
3Leerink Partners LLC21.00%4,032,000 shares
4Guggenheim Securities, LLC12.00%2,304,000 shares

Ratio = institution commitment ÷ complete source-table total (19,200,000 shares) × 100.

Source and calculation

Allocation ratios are calculated from each reported commitment and the complete total in the same source table; they are not ownership or fee percentages.

Underwriting purchase commitments as disclosed; shares; source class retained in the column header; source column: Number ofShares

Number ofShares

SEC table 605 row 8; source 1757454:1760975; SHA256 93f52a681b11ff1ee1d1ac8eb385a6f81a13749bd7c1ec7cd046b9af767b23d2

Goldman Sachs & Co. LLC: 7488000 / 19200000 × 100

Jefferies LLC: 5376000 / 19200000 × 100

Leerink Partners LLC: 4032000 / 19200000 × 100

Guggenheim Securities, LLC: 2304000 / 19200000 × 100

Source · 424B4 ↗

Underwriting terms

Underwriting terms
MeasureReported valueUnit
Underwriting discount per share$1.26$ / share
Total underwriting discount$24,192,000$
Source and calculation

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Underwriting discount per share

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Total underwriting discount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 4; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗

IPO CAPITAL QUALITY

Offering price $ / share$18
Gross offering amount $$345,600,000
Shares offered Shares19,200,000
Underwriting discount per share $ / share$1.26
Basis and evidence

No estimate is substituted for missing offer terms.

Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered19,200,000Shares
Offering price$18$ / share
Gross offering amount$345,600,000$
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 41 row 2; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

Gross offering amount

Base prospectus offering; cover per-share and total columns

SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗
IPO investors$345.60Mgross offer size
Issuer / selling holdersSee 424Bprimary-secondary split
Reported revenuePre-revenue—
Net result$(111.18M)latest reported basis
Future supplyLock-upreview holder-specific terms

Dilution and valuation

IPO price$18Final
Basic post-offer≈ 63.238M
Equity value≈ $1.1383B
Dilution and valuation
CalculationSharesValueReference
Base post-offer valuation≈ 63.238M≈ $1.1383B
Derived calculationFinalshares · $Basis and evidence 10 ↗
Post-offer shares — base/no option63,238,030—
Reported sourcePost-offer · BasesharesBasis and evidence 8 ↗
Post-offer shares — full option66,118,030—
Reported sourcePost-offer · Full optionsharesBasis and evidence 8 ↗
Capitalization shares — actual925,193—
Reported sourceCommon stock; actualsharesBasis and evidence 3 ↗
Capitalization shares — pro forma44,038,030—
Reported sourceCommon stock; pro formasharesBasis and evidence 4 ↗
Capitalization shares — pro forma as adjusted63,238,030—
Reported sourceCommon stock; pro forma as adjustedsharesBasis and evidence 5 ↗
Shares offered19,200,000—
Reported sourcesharesBasis and evidence 6 ↗
Offering price—$18
Reported sourceFinal$/shareBasis and evidence 7 ↗
Gross offering amount—$345,600,000
Reported source$Basis and evidence 7 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 41 row 6 columns 3; share summary; label column 1; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

Basis and evidence 2

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 41 row 6 columns 3; share summary; label column 1; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

Basis and evidence 3

Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 315 row 14 columns 1; share summary; label column 1; source 752516:767999; SHA256 021f77463b9f7b73251ce846fce95741d80366a9c2ede2bb68cca7d6c8913688 ↗

Basis and evidence 4

Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 315 row 14 columns 1; share summary; label column 1; source 752516:767999; SHA256 021f77463b9f7b73251ce846fce95741d80366a9c2ede2bb68cca7d6c8913688 ↗

Basis and evidence 5

Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator

Figures retain their stated source scenario and conditions.

SEC table 315 row 14 columns 1; share summary; label column 1; source 752516:767999; SHA256 021f77463b9f7b73251ce846fce95741d80366a9c2ede2bb68cca7d6c8913688 ↗

Basis and evidence 6

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 41 row 2; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

Basis and evidence 7

Base prospectus offering; cover per-share and total columns

Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.

SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗

Basis and evidence 8

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Offering price: $18

Exact input · Post-offer shares — base/no option: 63,238,030

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — full option: 66,118,030

SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗

SEC table 41 row 6 columns 3; share summary; label column 1; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

SEC valuation primary issuer cover; source 1492:1776; SHA256 830843816c17f5531aa1475b5312cdc53a564428f31f5f5f937bfe8527d6e785 ↗

SEC valuation summary conditions; source 105009:148174; SHA256 4a0d0cdd18be3dbe2f59568485f0164931f2b6efbf8684f0c234c064b1b375ef ↗

SEC valuation summary conditions; source 95392:99708; SHA256 66a18b1dd9091c0b65e45a1c0ccc1cc51feabd62fa2f5e378195303bd017b953 ↗

Basis and evidence 10

completion-of-this-offering

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Base prospectus offering; cover per-share and total columns

Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Exact input · Post-offer shares — base/no option: 63,238,030

Exact input · Offering price: $18

SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗

SEC table 41 row 6 columns 3; share summary; label column 1; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗

SEC valuation primary issuer cover; source 1492:1776; SHA256 830843816c17f5531aa1475b5312cdc53a564428f31f5f5f937bfe8527d6e785 ↗

SEC valuation summary conditions; source 105009:148174; SHA256 4a0d0cdd18be3dbe2f59568485f0164931f2b6efbf8684f0c234c064b1b375ef ↗

SEC valuation summary conditions; source 95392:99708; SHA256 66a18b1dd9091c0b65e45a1c0ccc1cc51feabd62fa2f5e378195303bd017b953 ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Offering completion · $18 × ≈ 63.238M shares · Final

Implied equity value≈ $1.1383BPrice × post-offer shares
Post-offer shares≈ 63.238MShare count, not tradable float
Existing-holder ownership reduction0.0%Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Prior saved context

These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.

IPO price · 19.200M · $345.60M · $18.00

Latest shares outstanding · 63.24M · $1.41B · Market snapshot

Revenue reference · — · Pre-revenue · —

Net-result reference · — · $(111.18M) · Loss-making

$18 × 63,238,030 = $1,138,284,540 [summary-table-41-base-6-price, summary-table-41-base-6-post]

Exact calculation · Derived whole-issuer equity value: $1,138,284,540

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesComparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗
CONTROLLING PARTYNo controlling party conclusion available

Latest available filing

Economic
~30.4%*
As of
2026/08/07
!Review the beneficial-ownership table and voting rights togetherView source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Latigo Biotherapeutics
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
our executive officers, directors and stockholders whoOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: owned; primary source clause; full source conditions retained; source scope: of our outstanding common stock before this offering and their respective affiliates will,; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Westlake BioPartnersOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Foresite CapitalOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with 5AM VenturesOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Westlake BioPartnersOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Blue Owl HealthcareOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Westlake BioPartnersOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with 5AM VenturesOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Foresite CapitalOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Foresite CapitalOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Blue Owl HealthcareOwnership as disclosed—>5%Beneficial—
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partitionDisclosedEvidence
Entities affiliated with Westlake BioPartnersBeneficial shares13,199,669——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Entities affiliated with Westlake BioPartnersBeneficial shares13,199,669——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Entities affiliated with Foresite CapitalBeneficial shares9,041,328——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Entities affiliated with Foresite CapitalBeneficial shares9,041,328——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Entities affiliated with 5AM VenturesBeneficial shares7,325,962——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Entities affiliated with 5AM VenturesBeneficial shares7,325,962——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Entities affiliated with Blue Owl HealthcareBeneficial shares3,146,780——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Entities affiliated with Blue Owl HealthcareBeneficial shares3,146,780——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Deep Track Biotechnology Master Fund, Ltd.Beneficial shares2,496,656——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Deep Track Biotechnology Master Fund, Ltd.Beneficial shares2,496,656——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Nima FarzanBeneficial shares2,902,419——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Nima FarzanBeneficial shares2,902,419——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Entities affiliated with Westlake BioPartnersBeneficial ownership—29.9%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Entities affiliated with Westlake BioPartnersBeneficial ownership—20.9%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Entities affiliated with Foresite CapitalBeneficial ownership—20.5%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Entities affiliated with Foresite CapitalBeneficial ownership—14.3%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Entities affiliated with 5AM VenturesBeneficial ownership—16.6%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Entities affiliated with 5AM VenturesBeneficial ownership—11.6%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Entities affiliated with Blue Owl HealthcareBeneficial ownership—7.1%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Entities affiliated with Blue Owl HealthcareBeneficial ownership—5%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Deep Track Biotechnology Master Fund, Ltd.Beneficial ownership—5.7%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Deep Track Biotechnology Master Fund, Ltd.Beneficial ownership—3.9%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Nima FarzanBeneficial ownership—6.2%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Nima FarzanBeneficial ownership—4.4%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
Timothy LugoBeneficial shares166,354——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Timothy LugoBeneficial shares166,354——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Neil Singla, M.D.Beneficial shares532,795——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Neil Singla, M.D.Beneficial shares532,795——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Timothy P. WalbertBeneficial shares329,819——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Timothy P. WalbertBeneficial shares329,819——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Sara BonsteinBeneficial shares105,542——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Sara BonsteinBeneficial shares105,542——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Beth Seidenberg, M.D.Beneficial shares13,199,669——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
Beth Seidenberg, M.D.Beneficial shares13,199,669——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
James B. Tananbaum, M.D.Beneficial shares9,041,328——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
James B. Tananbaum, M.D.Beneficial shares9,041,328——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
Neil Singla, M.D.Beneficial ownership—1.2%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Beth Seidenberg, M.D.Beneficial ownership—29.9%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
Beth Seidenberg, M.D.Beneficial ownership—20.9%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
James B. Tananbaum, M.D.Beneficial ownership—20.5%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
James B. Tananbaum, M.D.Beneficial ownership—14.3%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial ownership—54.8%Beneficial—
SharesBeneficially OwnedPrior to Offering; PercentageDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial ownership—39.2%Beneficial—
SharesBeneficially OwnedAfter Offering; PercentageDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial shares26,383,468——
SharesBeneficially OwnedPrior to Offering; NumberDisclosedEvidence
All directors and executive officers as a group (11 persons)Beneficial shares26,383,468——
SharesBeneficially OwnedAfter Offering; NumberDisclosedEvidence
our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed—approximately 55.8%Beneficial—
Upon closing of this offering; complete collective group includes executive officers,directors,pre-offering>5%stockholders and their respective affiliates. March31,2026share basis after PreferredStockConversion and ConvertibleNotesConversion; no group offering purchases,no underwriter option exercise,and no outstanding-option exercise. Original paragraph continues across printed page89; not individual or additive ownership.DisclosedEvidence
common stockper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retainedDisclosedEvidence
Source and calculation ↗
our executive officers, directors and stockholders who · our executive officers, directors and stockholders who — Ownership as disclosed · >5%

Source statement; >; source predicate: owned; primary source clause; full source conditions retained; source scope: of our outstanding common stock before this offering and their respective affiliates will,; not an additive ownership partition

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will,

0001193125-26-340329 · SEC ownership paragraph; source 658206:658506; SHA256 9949b9bd8dc66d421585d03d95a3063bfac2d4480e8b8c57eaed21f5b42d7fb2 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Consists of (i) 346,407 shares of Series A-2 Preferred purchased by Westlake BioPartners Fund I, L.P.; (ii) 1,385,629 shares of Series A-2 Preferred purchased by Westlake BioPartners Opportunity Fund I, L.P.; and (iii) 3,464,072 shares of Series A-2 Preferred purchased by Westlake BioPartners Fund II, L.P. Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding stock. Dr. Seidenberg, a member of our board of directors, is a managing director of Westlake BioPartners.

0001193125-26-340329 · SEC ownership paragraph; source 1593138:1593861; SHA256 cd7d030bf69a2f2a79f4ba47cfead8c071ccfde3b0cbb33e5a0c54ab02f550f2 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Consists of (i) 1,558,832 shares of Series A-2 Preferred purchased by Foresite Capital Fund V, L.P.; (ii) 1,558,832 shares of Series A-2 Preferred purchased by Foresite Capital Opportunity Fund V, L.P.; and (iii) 779,416 shares of Series A-2 Preferred purchased by Foresite Capital Fund VI LP. Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.

0001193125-26-340329 · SEC ownership paragraph; source 1594131:1594851; SHA256 d7271977e412c1d7d0f4a77667b020d5e535d36635985efedd25f7f06365ec58 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Consists of (i) 866,018 shares of Series A-2 Preferred purchased by 5AM Opportunities II, L.P.; and (ii) 866,018 shares of Series A-2 Preferred purchased by 5AM Ventures VI, L.P. Entities affiliated with 5AM Ventures hold more than 5% of our outstanding capital stock. Dr. Palestrant, a former member of our board of directors, is a partner at 5AM Ventures. Dr. Palestrant resigned from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part

0001193125-26-340329 · SEC ownership paragraph; source 1595121:1595844; SHA256 206b3f1443d0706663c17f4d057d76fcac2fac8bd03c5b01343f493e443f9061 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

In February 2024, we issued and sold to entities affiliated with Westlake BioPartners an aggregate of 154,137 shares of our common stock at a purchase price of $2.19 per share for aggregate cash proceeds of approximately $0.3 million. 79,326 shares of our common stock were purchased by Westlake BioPartners Fund I, L.P., 27,956 shares of our common stock were purchased by Westlake BioPartners Opportunity Fund I, L.P. and 46,855 shares of our common stock were purchased by Westlake BioPartners Fund II, L.P. Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding capital stock. Dr. Seidenberg, a member of our board of directors, is a managing director at Westlake BioPartners.

0001193125-26-340329 · SEC ownership paragraph; source 1595994:1596814; SHA256 3c645b3f8130cb31971079b622da2b6e94422e6bf1eec213553204c928abbed5 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Consists of (i) 2,865,054 shares of Series B Preferred purchased by Blue Owl Healthcare Opportunities IV LP; and (ii) 103,749 shares of Series B Preferred purchased by Blue Owl Healthcare Opportunities EF IV LP. Entities affiliated with Blue Owl Healthcare hold more than 5% of our outstanding stock. Mr. Raidy, a member of our board of directors, is a senior managing director of Blue Owl Healthcare.

0001193125-26-340329 · SEC ownership paragraph; source 1602079:1602586; SHA256 5502300303b2a1a12e7757eeeb240dccc88198d5c1db5262875a874517c49da1 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding stock. Dr. Seidenberg, a member of our board of directors, is a managing director at Westlake BioPartners.

0001193125-26-340329 · SEC ownership paragraph; source 1602856:1603151; SHA256 f1a41c89e85cf0f26910cd028314d80001abfe6fd674ee05f607cc84d9b86ab0 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition

Entities affiliated with 5AM Ventures hold more than 5% of our outstanding capital stock. Dr. Palestrant, a former member of our board of directors, is a partner at 5AM Ventures. Dr. Palestrant resigned from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part

0001193125-26-340329 · SEC ownership paragraph; source 1603421:1603880; SHA256 ba4de97eaae2e959bf53fb939522c8a8b2f5c27d6f8461b263734497d4375780 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Consists of (i) 445,320 shares of Series B Preferred purchased by Foresite Capital Fund V, L.P.; (ii) 296,880 shares of Series B Preferred purchased by Foresite Capital Opportunity Fund V, L.P.; and (iii) 742,201 shares of Series B Preferred purchased by Foresite Capital Fund VI LP. Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.

0001193125-26-340329 · SEC ownership paragraph; source 1604150:1604740; SHA256 947aa71eec1c93ae33313b6cd6335ce54bc83268c1a61a2054bd41eb1882bd47 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.

0001193125-26-340329 · SEC ownership paragraph; source 1608567:1608868; SHA256 b2de1cc58b8ba683c1cbd36f0ff14f1f24e2b1933acbc15ffbc8d20d9ff463b9 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Ownership as disclosed · >5%

Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition

Entities affiliated with Blue Owl Healthcare hold more than 5% of our outstanding stock. Mr. Raidy, a member of our board of directors, is a senior managing director of Blue Owl Healthcare.

0001193125-26-340329 · SEC ownership paragraph; source 1609138:1609428; SHA256 15e38080e23c052220ad9e6b6edf7471d86969ff972c042f6fece0704ab1f75f ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Beneficial shares · 13,199,669

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Westlake BioPartners(1)

0001193125-26-340329 · SEC table 545 row 5 columns 4; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:3 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Beneficial shares · 13,199,669

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Westlake BioPartners(1)

0001193125-26-340329 · SEC table 545 row 5 columns 12; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:9 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Beneficial shares · 9,041,328

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Foresite Capital(2)

0001193125-26-340329 · SEC table 545 row 6 columns 4; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:3 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Beneficial shares · 9,041,328

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Foresite Capital(2)

0001193125-26-340329 · SEC table 545 row 6 columns 12; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:9 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Beneficial shares · 7,325,962

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with 5AM Ventures(3)

0001193125-26-340329 · SEC table 545 row 7 columns 4; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:3 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Beneficial shares · 7,325,962

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with 5AM Ventures(3)

0001193125-26-340329 · SEC table 545 row 7 columns 12; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:9 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Beneficial shares · 3,146,780

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Blue Owl Healthcare(4)

0001193125-26-340329 · SEC table 545 row 8 columns 4; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:3 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Beneficial shares · 3,146,780

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Blue Owl Healthcare(4)

0001193125-26-340329 · SEC table 545 row 8 columns 12; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:9 ↗

Deep Track Biotechnology Master Fund, Ltd. · Deep Track Biotechnology Master Fund, Ltd. — Beneficial shares · 2,496,656

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)

0001193125-26-340329 · SEC table 545 row 9 columns 4; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:3 ↗

Deep Track Biotechnology Master Fund, Ltd. · Deep Track Biotechnology Master Fund, Ltd. — Beneficial shares · 2,496,656

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)

0001193125-26-340329 · SEC table 545 row 9 columns 12; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:9 ↗

Nima Farzan · Nima Farzan — Beneficial shares · 2,902,419

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Nima Farzan(6)

0001193125-26-340329 · SEC table 546 row 5 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Nima Farzan · Nima Farzan — Beneficial shares · 2,902,419

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Nima Farzan(6)

0001193125-26-340329 · SEC table 546 row 5 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Beneficial ownership · 29.9%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Westlake BioPartners(1)

0001193125-26-340329 · SEC table 545 row 5 columns 8,9; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:6 ↗

Entities affiliated with Westlake BioPartners · Entities affiliated with Westlake BioPartners — Beneficial ownership · 20.9%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Westlake BioPartners(1)

0001193125-26-340329 · SEC table 545 row 5 columns 16,17; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:12 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Beneficial ownership · 20.5%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Foresite Capital(2)

0001193125-26-340329 · SEC table 545 row 6 columns 8,9; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:6 ↗

Entities affiliated with Foresite Capital · Entities affiliated with Foresite Capital — Beneficial ownership · 14.3%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Foresite Capital(2)

0001193125-26-340329 · SEC table 545 row 6 columns 16,17; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:12 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Beneficial ownership · 16.6%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with 5AM Ventures(3)

0001193125-26-340329 · SEC table 545 row 7 columns 8,9; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:6 ↗

Entities affiliated with 5AM Ventures · Entities affiliated with 5AM Ventures — Beneficial ownership · 11.6%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with 5AM Ventures(3)

0001193125-26-340329 · SEC table 545 row 7 columns 16,17; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:12 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Beneficial ownership · 7.1%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Blue Owl Healthcare(4)

0001193125-26-340329 · SEC table 545 row 8 columns 8,9; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:6 ↗

Entities affiliated with Blue Owl Healthcare · Entities affiliated with Blue Owl Healthcare — Beneficial ownership · 5%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Blue Owl Healthcare(4)

0001193125-26-340329 · SEC table 545 row 8 columns 16,17; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:12 ↗

Deep Track Biotechnology Master Fund, Ltd. · Deep Track Biotechnology Master Fund, Ltd. — Beneficial ownership · 5.7%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)

0001193125-26-340329 · SEC table 545 row 9 columns 8,9; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:3,3:6 ↗

Deep Track Biotechnology Master Fund, Ltd. · Deep Track Biotechnology Master Fund, Ltd. — Beneficial ownership · 3.9%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)

0001193125-26-340329 · SEC table 545 row 9 columns 16,17; source 1631053:1638305; SHA256 4b9cff270ee9be9e5ee4662554fc8dccbf04841f2f121c8c2e73a2ccf4c5feb0; ownership header cells 2:6,3:12 ↗

Nima Farzan · Nima Farzan — Beneficial ownership · 6.2%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Nima Farzan(6)

0001193125-26-340329 · SEC table 546 row 5 columns 8,9; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:6 ↗

Nima Farzan · Nima Farzan — Beneficial ownership · 4.4%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Nima Farzan(6)

0001193125-26-340329 · SEC table 546 row 5 columns 16,17; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:12 ↗

Timothy Lugo · Timothy Lugo — Beneficial shares · 166,354

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Timothy Lugo(7)

0001193125-26-340329 · SEC table 546 row 6 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Timothy Lugo · Timothy Lugo — Beneficial shares · 166,354

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Timothy Lugo(7)

0001193125-26-340329 · SEC table 546 row 6 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Neil Singla, M.D. · Neil Singla, M.D. — Beneficial shares · 532,795

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Neil Singla, M.D.(8)

0001193125-26-340329 · SEC table 546 row 7 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Neil Singla, M.D. · Neil Singla, M.D. — Beneficial shares · 532,795

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Neil Singla, M.D.(8)

0001193125-26-340329 · SEC table 546 row 7 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Timothy P. Walbert · Timothy P. Walbert — Beneficial shares · 329,819

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Timothy P. Walbert(9)

0001193125-26-340329 · SEC table 546 row 8 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Timothy P. Walbert · Timothy P. Walbert — Beneficial shares · 329,819

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Timothy P. Walbert(9)

0001193125-26-340329 · SEC table 546 row 8 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Sara Bonstein · Sara Bonstein — Beneficial shares · 105,542

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Sara Bonstein(10)

0001193125-26-340329 · SEC table 546 row 9 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Sara Bonstein · Sara Bonstein — Beneficial shares · 105,542

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Sara Bonstein(10)

0001193125-26-340329 · SEC table 546 row 9 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial shares · 13,199,669

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Beth Seidenberg, M.D.(12)

0001193125-26-340329 · SEC table 546 row 12 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial shares · 13,199,669

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Beth Seidenberg, M.D.(12)

0001193125-26-340329 · SEC table 546 row 12 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

James B. Tananbaum, M.D. · James B. Tananbaum, M.D. — Beneficial shares · 9,041,328

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: James B. Tananbaum, M.D.(13)

0001193125-26-340329 · SEC table 546 row 14 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

James B. Tananbaum, M.D. · James B. Tananbaum, M.D. — Beneficial shares · 9,041,328

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: James B. Tananbaum, M.D.(13)

0001193125-26-340329 · SEC table 546 row 14 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

Neil Singla, M.D. · Neil Singla, M.D. — Beneficial ownership · 1.2%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Neil Singla, M.D.(8)

0001193125-26-340329 · SEC table 546 row 7 columns 8,9; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:6 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial ownership · 29.9%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Beth Seidenberg, M.D.(12)

0001193125-26-340329 · SEC table 546 row 12 columns 8,9; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:6 ↗

Beth Seidenberg, M.D. · Beth Seidenberg, M.D. — Beneficial ownership · 20.9%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Beth Seidenberg, M.D.(12)

0001193125-26-340329 · SEC table 546 row 12 columns 16,17; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:12 ↗

James B. Tananbaum, M.D. · James B. Tananbaum, M.D. — Beneficial ownership · 20.5%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: James B. Tananbaum, M.D.(13)

0001193125-26-340329 · SEC table 546 row 14 columns 8,9; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:6 ↗

James B. Tananbaum, M.D. · James B. Tananbaum, M.D. — Beneficial ownership · 14.3%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: James B. Tananbaum, M.D.(13)

0001193125-26-340329 · SEC table 546 row 14 columns 16,17; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:12 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial ownership · 54.8%

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340329 · SEC table 546 row 15 columns 8,9; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:6 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial ownership · 39.2%

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340329 · SEC table 546 row 15 columns 16,17; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:12 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial shares · 26,383,468

Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340329 · SEC table 546 row 15 columns 4; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:3,3:3 ↗

All directors and executive officers as a group (11 persons) · All directors and executive officers as a group (11 persons) — Beneficial shares · 26,383,468

Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition

Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)

0001193125-26-340329 · SEC table 546 row 15 columns 12; source 1638791:1651358; SHA256 78dd2e7ea3a9e9696cf4f903e5c4b70ca8f41e4cc8daec233d167f01777550c5; ownership header cells 2:6,3:9 ↗

our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates · our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates — Ownership as disclosed · approximately 55.8%

Upon closing of this offering; complete collective group includes executive officers,directors,pre-offering>5%stockholders and their respective affiliates. March31,2026share basis after PreferredStockConversion and ConvertibleNotesConversion; no group offering purchases,no underwriter option exercise,and no outstanding-option exercise. Original paragraph continues across printed page89; not individual or additive ownership.

Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, 89 Table of Contents in the aggregate, hold approximately 55.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026, after giving effect to the Preferred Stock Conversion and Convertible Notes Conversion, and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.

0001193125-26-340329 · SEC ownership paragraph; source 658206:660442; SHA256 59da1b92d76ac07d244cb6dac917c67a3e5c8036868a3edd06a987570f7c5a33 ↗

common stock · common stock — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained

Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 999,999,999 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law (DGCL). This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.

0001193125-26-340329 · SEC ownership excerpt; source 1669614:1670003; SHA256 62b3f11f4409e698a7800ffb9d74bd44f8ed31c78c944db111514caaaa4fce0d; context source 1667265:1668406; SHA256 047eecdbde569d67816fd839c5c3e651a7ce45227266af6e9d59c420028d1c20 ↗

Saved control snapshot

The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.

Saved control snapshot
Holder / measureSharesOwnershipVoting rightsReference
Existing holdersMajor ownership group—~69.6%*—
2026/08/07Latest available filing424B4 ↗
Other disclosed classesMajor ownership group—See filing—
2026/08/07Latest available filing424B4 ↗
IPO sharesPublic / new investors—19.200M—
2026/08/07Latest available filing424B4 ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

POTENTIAL SUPPLY PRESSURERequires holder-level review

IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.

Initial float
19.200M
Restricted / potential supply
63.24M
Multiple
See filing
Increase
See filing

Share supply

Source lock-up conditions

Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stockAfter date of this prospectus · Source conditions apply180 days
We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or exchangeable for our common stockAfter date of this prospectus · Source conditions apply180 days
Source and calculation
our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock

Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares of our common stock, could reduce the market price of our common stock. After this offering, we will have 63,238,030 shares of our common stock outstanding (assuming no exercise of the underwriters’ option to purchase additional shares of our common stock). This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Substantially all of the remaining shares of our common stock initially will be restricted as a result of securities laws, market standoff provisions or lock-up agreements, but will become eligible to be sold after this offering as described in the section titled “Shares Eligible for Future Sale.” We, our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock have entered into market standoff agreements with us and have entered or will enter into lock-up agreements under which we have agreed or will agree, subject to specific exceptions described in the section titled “Underwriting,” not to offer, sell, or transfer such securities for 180 days following the date of this prospectus. We refer to such period as the lock-up period. Goldman Sachs & Co. LLC, Jefferies LLC and Leerink Partners LLC may, in their sole discretion and at any time or from time to time before the termination of the lock-up period release all or any portion of the securities subject to lock-up agreements.

SEC lock-up paragraph; source 660771:662871; SHA256 08a47f880d064ed30e29d22eaccf1cda5c2dfb974f9d97927b7373edea8d43f5 ↗
We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or exchangeable for our common stock

We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for shares of common stock, or collectively, the “Lock-Up Securities,” during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of Goldman Sachs & Co. LLC, Jefferies LLC and Leerink Partners LLC. This agreement does not apply to any existing employee benefit plans. See the section titled “Shares Available for Future Sale” for a discussion of certain transfer restrictions.

SEC lock-up paragraph; source 1765009:1765963; SHA256 9c9d674e753605a6aec7a63997e9a4a7af516081a1142ec6ae5549c099eb7054 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
Over-allotment windowPost-listing See filing · Additional shares only if exercisedOver-allotment window · Additional shares only if exercised
Insider resale eligibilityHolder-specific See 424B · Existing-holder supplyInsider resale eligibility · Existing-holder supply
Basis and evidence
Over-allotment window

Over-allotment window · Additional shares only if exercised

Lock-up / shares eligible for future sale ↗
Insider resale eligibility

Insider resale eligibility · Existing-holder supply

Lock-up / shares eligible for future sale ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Operating cash flow

$ · Annual values as reported
FY2024($50,955,000)
FY2025($97,557,000)
Financial quality
CalculationFY2024FY2025
Operating cash flow($50,955,000)($97,557,000)
Financial quality
CalculationReported value
Cash and cash equivalents2024-12-31$17,918,000
Cash and cash equivalents2025-12-31$69,437,000
Current assets2024-12-31$21,164,000
Current assets2025-12-31$73,829,000
Total assets2024-12-31$22,864,000
Total assets2025-12-31$75,516,000
Current liabilities2024-12-31$14,435,000
Current liabilities2025-12-31$18,446,000
Total liabilities2024-12-31$14,934,000
Total liabilities2025-12-31$18,608,000
Total equity / (deficit)2024-12-31($129,599,000)
Total equity / (deficit)2025-12-31($231,674,000)
General and administrative expensesFY2024$6,667,000
General and administrative expensesFY2025$10,862,000
Cash and cash equivalents2025-12-31 · Unaudited$69,437,000
Cash and cash equivalents2026-03-31 · Unaudited$42,177,000
Current assets2025-12-31 · Unaudited$73,829,000
Current assets2026-03-31 · Unaudited$46,843,000
Total assets2025-12-31 · Unaudited$75,516,000
Total assets2026-03-31 · Unaudited$50,581,000
Current liabilities2025-12-31 · Unaudited$18,446,000
Current liabilities2026-03-31 · Unaudited$14,491,000
Total liabilities2025-12-31 · Unaudited$18,608,000
Total liabilities2026-03-31 · Unaudited$14,578,000
Total equity / (deficit)2025-12-31 · Unaudited($231,674,000)
Total equity / (deficit)2026-03-31 · Unaudited($252,579,000)
General and administrative expenses3M ended 2025-03-31 · Unaudited$2,824,000
General and administrative expenses3M ended 2026-03-31 · Unaudited$5,803,000
Operating cash flow3M ended 2025-03-31 · Unaudited($21,157,000)
Operating cash flow3M ended 2026-03-31 · Unaudited($27,069,000)
Basis and evidence
Cash and cash equivalents
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Cash and cash equivalents
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total assets
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total liabilities
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
December 31, 2024; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2024-12-31
Total stockholders’ deficit
December 31, 2025; issuer; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
General and administrative
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
General and administrative
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; currency symbol as printed ($); ISO currency not assigned; year ended 2025-12-31
Cash and cash equivalents
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Cash and cash equivalents
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total assets
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total assets
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total current liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total current liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total liabilities
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total liabilities
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
Total stockholders’ deficit
December 31, 2025; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2025-12-31
Total stockholders’ deficit
March 31, 2026; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; as of 2026-03-31
General and administrative
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
General and administrative
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Net cash used in operating activities
3M ended 2025-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2025-03-31
Net cash used in operating activities
3M ended 2026-03-31; issuer unaudited; currency symbol as printed ($); ISO currency not assigned; 3 months ended 2026-03-31
Saved snapshot — period not verified

These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.

Financial quality

Financial quality
CalculationReported value
RevenuePre-revenue
Net resultLatest reported$(111.18M)
Market-value referencePost-listing snapshot$1.41B
Shares outstandingLatest reported63.24M
Offer size19.200M$345.60M
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Financial reviewReported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open 424B4 ↗
Evidence 01Final prospectus source verified

Why it mattersChanges dilution, public float and potential supply.

Evidence · 424B4 · 2026/08/07
Evidence 02Trading began on 2026-08-07 at $18.00

Why it mattersChanges valuation, proceeds and first-day return assumptions.

Evidence · 424B4 · 2026/08/07
IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.
2026/08/07
424B4

• Final prospectus source verified

• Trading began on 2026-08-07 at $18.00

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Risk 3

The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.

Potential impact
High
Risk 4

Option exercise, employee equity and lock-up expiry can expand tradable supply.

Potential impact
Medium
Document424B4SEC source document
Filed2026-08-07SEC EDGAR
Research as of2026/08/071 public filings identified
Source-bound table inputs91SEC EDGAR
Open filing ↗
Sources and calculation notes

Final prospectus, offer price, listing date and headline financial evidence reconciled

View the filing's actual first page
Latigo Biotherapeutics, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR